<?xml version='1.0' encoding='utf-8'?>
<document id="16988521"><sentence text="Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide."><entity charOffset="41-51" id="DDI-PubMed.16988521.s1.e0" text="tipranavir" /><entity charOffset="52-61" id="DDI-PubMed.16988521.s1.e1" text="ritonavir" /><entity charOffset="66-77" id="DDI-PubMed.16988521.s1.e2" text="enfuvirtide" /><pair ddi="false" e1="DDI-PubMed.16988521.s1.e0" e2="DDI-PubMed.16988521.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16988521.s1.e0" e2="DDI-PubMed.16988521.s1.e1" /><pair ddi="false" e1="DDI-PubMed.16988521.s1.e0" e2="DDI-PubMed.16988521.s1.e2" /><pair ddi="false" e1="DDI-PubMed.16988521.s1.e1" e2="DDI-PubMed.16988521.s1.e1" /><pair ddi="false" e1="DDI-PubMed.16988521.s1.e1" e2="DDI-PubMed.16988521.s1.e2" /></sentence><sentence text="Fifty-five patients placed on tipranavir/ritonavir 500/200 mg twice a day (27 with enfuvirtide and 28 without) underwent tipranavir and ritonavir plasma concentration measurements by high-pressure liquid chromatography"><entity charOffset="30-40" id="DDI-PubMed.16988521.s2.e0" text="tipranavir" /><entity charOffset="41-50" id="DDI-PubMed.16988521.s2.e1" text="ritonavir" /><entity charOffset="83-94" id="DDI-PubMed.16988521.s2.e2" text="enfuvirtide" /><entity charOffset="121-131" id="DDI-PubMed.16988521.s2.e3" text="tipranavir" /><entity charOffset="136-145" id="DDI-PubMed.16988521.s2.e4" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e0" e2="DDI-PubMed.16988521.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e0" e2="DDI-PubMed.16988521.s2.e1" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e0" e2="DDI-PubMed.16988521.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e0" e2="DDI-PubMed.16988521.s2.e3" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e0" e2="DDI-PubMed.16988521.s2.e4" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e1" e2="DDI-PubMed.16988521.s2.e1" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e1" e2="DDI-PubMed.16988521.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e1" e2="DDI-PubMed.16988521.s2.e3" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e1" e2="DDI-PubMed.16988521.s2.e4" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e2" e2="DDI-PubMed.16988521.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e2" e2="DDI-PubMed.16988521.s2.e3" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e2" e2="DDI-PubMed.16988521.s2.e4" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e3" e2="DDI-PubMed.16988521.s2.e3" /><pair ddi="false" e1="DDI-PubMed.16988521.s2.e3" e2="DDI-PubMed.16988521.s2.e4" /></sentence><sentence text=" Markedly higher tipranavir and ritonavir trough concentrations were observed in enfuvirtide recipients"><entity charOffset="17-27" id="DDI-PubMed.16988521.s3.e0" text="tipranavir" /><entity charOffset="32-41" id="DDI-PubMed.16988521.s3.e1" text="ritonavir" /><entity charOffset="81-92" id="DDI-PubMed.16988521.s3.e2" text="enfuvirtide" /><pair ddi="false" e1="DDI-PubMed.16988521.s3.e0" e2="DDI-PubMed.16988521.s3.e0" /><pair ddi="false" e1="DDI-PubMed.16988521.s3.e0" e2="DDI-PubMed.16988521.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16988521.s3.e0" e2="DDI-PubMed.16988521.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16988521.s3.e1" e2="DDI-PubMed.16988521.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16988521.s3.e1" e2="DDI-PubMed.16988521.s3.e2" /></sentence><sentence text=" The modelling of sparse plasma samples using a first order absorption and elimination monocompartmental model without time lag predicted higher tipranavir elimination half-life and volume of distribution in enfuvirtide takers"><entity charOffset="145-155" id="DDI-PubMed.16988521.s4.e0" text="tipranavir" /><entity charOffset="208-219" id="DDI-PubMed.16988521.s4.e1" text="enfuvirtide" /><pair ddi="false" e1="DDI-PubMed.16988521.s4.e0" e2="DDI-PubMed.16988521.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16988521.s4.e0" e2="DDI-PubMed.16988521.s4.e1" /></sentence><sentence text=" This unexpected drug-drug interaction warrants further investigation" /><sentence text="" /></document>